Nassour Anthony-Joe, Jain Anika, Khanani Hadia, Hui Nicholas, Thompson Nadine J, Sorensen Brian, Baskaranathan Sris, Bergersen Philip, Chalasani Venu, Dean Thomas, Dias Max, Wines Michael, Symons James, Tarlinton Lisa, Woo Henry
Department of Urology, Sydney Adventist Hospital, Wahroonga, NSW 2076, Australia.
SAN Nuclear Medicine and Radiology, Sydney Adventist Hospital, Wahroonga, NSW 2076, Australia.
Cancers (Basel). 2025 Mar 12;17(6):960. doi: 10.3390/cancers17060960.
The maximum standardised uptake value (SUV) can potentially be affected by the uptake period during PSMA PET imaging. The optimal image acquisition period for 2-(3-{1-carboxy-5-[(6-18F-fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid (F-DCFPyL)PSMA PET/CT is yet to be established. This study aims to evaluate the effect of the uptake period on the SUV in diagnosing localised, clinically significant prostate cancer using F-DCFPyL-PSMA PET/CT.
Sixty biopsy-naive men with one or more PI-RADS 4 or 5 lesions of at least 10 mm on multiparametric MRI (mpMRI) were enrolled to undergo F-DCFPyL-PSMA PET/CT. SUV was prospectively measured following an uptake period of 60, 90 and 120 min post injection of F-DCFPyL-PSMA radiotracer. Concordance with biopsy results or final histopathology was recorded.
Mean absolute differences in SUV at 60 vs. 90, 60 vs. 120, and 90 vs. 120 min uptake periods were 3.23 (SD 4.76), 4.53 (SD 7.33), and 3.24 (SD 4.56), respectively. This represents a statistically significant systematic increase in SUV (-value < 0.001) with increasing uptake period. The interval between the uptake period of 60 vs. 120 min represented the largest SUV change of 29.98%.
The SUV is a dynamic variable significantly affected by uptake period. Our study supports image acquisition at 120 min following injection of F-DCFPyL radiotracer. Further studies are needed to determine if this acquisition period can be applied to other Fluorine-18 based PSMA radiotracers.
在前列腺特异性膜抗原（PSMA）正电子发射断层显像（PET）成像过程中，最大标准化摄取值（SUV）可能会受到摄取期的影响。2-(3-{1-羧基-5-[(6-18F-氟吡啶-3-羰基)-氨基]-戊基}-脲基)-戊二酸（F-DCFPyL）PSMA PET/CT的最佳图像采集期尚未确定。本研究旨在评估摄取期对使用F-DCFPyL-PSMA PET/CT诊断局限性、具有临床意义的前列腺癌时SUV的影响。
纳入60名未进行活检的男性，这些男性在多参数磁共振成像（mpMRI）上有一个或多个PI-RADS 4或5类、直径至少10 mm的病变，接受F-DCFPyL-PSMA PET/CT检查。在注射F-DCFPyL-PSMA放射性示踪剂后60、90和120分钟的摄取期后，前瞻性测量SUV。记录与活检结果或最终组织病理学的一致性。
在摄取期60分钟与90分钟、60分钟与120分钟、90分钟与120分钟时，SUV的平均绝对差异分别为3.23（标准差4.76）、4.53（标准差7.33）和3.24（标准差4.56）。这表明随着摄取期的延长，SUV有统计学意义的系统性增加（P值<0.001）。60分钟与120分钟摄取期之间的SUV变化最大，为29.98%。
SUV是一个受摄取期显著影响的动态变量。我们的研究支持在注射F-DCFPyL放射性示踪剂后120分钟进行图像采集。需要进一步研究以确定该采集期是否可应用于其他基于氟-18的PSMA放射性示踪剂。
